Epilepsy in pregnancy: Antiseizure medication selection and fetal risk

Authors

DOI:

https://doi.org/10.62827/fb.v27i10.1410

Keywords:

Epilepsy; Pregnancy; Anticonvulsants; Congenital Abnormalities.

Abstract

Epilepsy management during pregnancy requires effective prevention of maternal seizures while limiting avoidable fetal exposure to medications with structural and neurodevelopmental toxicity. Treatment decisions depend on the epilepsy syndrome, previous treatment response, medication dose, gestational timing, and the risks of modifying an effective treatment regimen. This narrative review examines comparative fetal risks, preconception planning, pharmacokinetic monitoring, folate supplementation, and care after delivery. Targeted PubMed searches and November 2026 guidance identified prospective pregnancy registries, developmental cohorts, pharmacokinetic investigations, population-based studies, and multidisciplinary recommendations. Evidence was synthesized descriptively without a new meta-analysis. The 2024 EURAP analysis reported major congenital malformations in 9.9% (153/1,549) of valproate-exposed pregnancies, compared with 3.1% (110/3,584) for lamotrigine, 2.9% (13/443) for oxcarbazepine, and 2.5% (33/1,325) for levetiracetam, within a nonrandomized monotherapy cohort. Valproate also has the most consistent association with adverse cognitive and developmental outcomes. Findings for topiramate vary by outcome and study design, with established concerns about oral clefts and fetal growth and uncertainty about neurodevelopmental effects. Lower observed malformation rates do not establish complete safety, and information remains limited for several newer agents. Pregnancy-related concentration declines require individualized monitoring, while postpartum normalization of clearance creates a risk of toxicity if increased doses are continued unchanged. Folate should be prescribed before conception and during pregnancy, although the optimal dose remains unsettled. An effective medication should not be abruptly discontinued after pregnancy recognition. Care combines syndrome-specific prescribing, informed discussion of absolute risks, planned monitoring, appropriate fetal assessment, and coordinated neurological and obstetric follow-up.

Author Biographies

  • Ana Claudia Recchia Barbosa, FAMERP

    Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brasil

  • Bárbara de Mello Galvani , UFTM

    Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brasil

  • Moisés de Souza Mello , Unisul

    Universidade do Sul de Santa Catarina (Unisul), Tubarão, SC, Brasil

  • Rebecca Vuolo Marques , UNISA

    Universidade Santo Amaro (UNISA), São Paulo, SP, Brasil

  • Gabriela Buffon, Universidade Feevale

    Universidade Feevale, Novo Hamburgo, RS, Brasil

  • Jaqueline Jácome Sachetti, FMJ

    Faculdade de Medicina de Jundiaí (FMJ), Jundiaí, SP, Brasil

  • Isabella Franco Barbosa Pesce, Uniara

    Universidade de Araraquara (Uniara), Araraquara, SP, Brasil

  • Gustavo da Rocha, UNESC

    Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brasil

  • Gustavo Pereira Reinaldo, UFSM

    Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil

  • Leonardo Schaucoski Cizeski, UNESC

    Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brasil

References

Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21(6):497-517. doi: 10.1684/epd.2019.1105.

Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244-52. doi: 10.1016/S1474-4422(12)70323-X.

Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, et al. Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. JAMA Neurol. 2022;79(4):370-379. doi: 10.1001/jamaneurol.2021.5487.

Pack AM, Oskoui M, Williams Roberson S, Donley DK, French J, Gerard EE, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology. 2024;102(11):e209279. doi: 10.1212/WNL.0000000000209279.

Pennell PB, French JA, May RC, Gerard E, Kalayjian L, Penovich P, et al. Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy. N Engl J Med. 2020;383(26):2547-2556. doi: 10.1056/NEJMoa2008663.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. Epilepsia. 2016;57(8):e173-7. doi: 10.1111/epi.13437.

Battino D, Tomson T, Bonizzoni E, Craig J, Perucca E, Sabers A, et al. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol. 2024;81(5):481-489. doi: 10.1001/jamaneurol.2024.0258.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538. doi: 10.1016/S1474-4422(18)30107-8.

Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, et al. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. Neurology. 2018;90(4):e342-e351. doi: 10.1212/WNL.0000000000004857.

Hernández-Díaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21-28. doi: 10.1097/AOG.0000000000000018.

Hernández-Díaz S, Straub L, Bateman BT, Zhu Y, Mogun H, Wisner KL, et al. Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure. N Engl J Med. 2024;390(12):1069-1079. doi: 10.1056/NEJMoa2309359.

Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol. 2022;79(7):672-681. doi: 10.1001/jamaneurol.2022.1269.

Madley-Dowd P, Ahlqvist VH, Forbes H, Rast JE, Martin FZ, Zhong C, et al. Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun. 2024;15(1):9640. doi: 10.1038/s41467-024-53813-1.

Straub L, Hernandez-Diaz S, Bateman BT, Zhu Y, Mogun H, Wisner KL, et al. Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study. BMJ. 2026;392:e085725. doi: 10.1136/bmj-2025-085725.

Meador KJ, Cohen MJ, Loring DW, Matthews AG, Brown C, Robalino CP, et al. Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study. Lancet Neurol. 2023;22(8):712-722. doi: 10.1016/S1474-4422(23)00199-0.

Meador KJ, Cohen MJ, Loring DW, Matthews AG, Brown C, Robalino CP, et al. Neuropsychological Outcomes in 6-Year-Old Children of Women With Epilepsy: A Prospective Nonrandomized Clinical Trial. JAMA Neurol. 2025;82(1):30-39. doi: 10.1001/jamaneurol.2024.3982.

Perucca P, Bourikas D, Voinescu PE, Vadlamudi L, Chellun D, Kumke T, et al. Lacosamide and pregnancy: Data from spontaneous and solicited reports. Epilepsia. 2024;65(5):1275-1284. doi: 10.1111/epi.17924.

Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22 Pt 2):2130-6. doi: 10.1212/01.wnl.0000289511.20864.2a.

Meador KJ, Pennell PB, May RC, Brown CA, Baker G, Bromley R, et al. Effects of periconceptional folate on cognition in children of women with epilepsy: NEAD study. Neurology. 2020;94(7):e729-e740. doi: 10.1212/WNL.0000000000008757.

Vegrim HM, Dreier JW, Alvestad S, Gilhus NE, Gissler M, Igland J, et al. Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy. JAMA Neurol. 2022;79(11):1130-1138. doi: 10.1001/jamaneurol.2022.2977.

Birnbaum AK, Meador KJ, Karanam A, Brown C, May RC, Gerard EE, et al. Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy. JAMA Neurol. 2020;77(4):441-450. doi: 10.1001/jamaneurol.2019.4443.

Downloads

Published

2026-11-20

How to Cite

Epilepsy in pregnancy: Antiseizure medication selection and fetal risk. (2026). Fisioterapia Brasil, 27(10), 7010-7024. https://doi.org/10.62827/fb.v27i10.1410

Most read articles by the same author(s)